FRX Stock Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.10 |
52 Week High | US$15.43 |
52 Week Low | US$9.27 |
Beta | 0.35 |
1 Month Change | 21.29% |
3 Month Change | -0.40% |
1 Year Change | 34.82% |
3 Year Change | 91.87% |
5 Year Change | 134.47% |
Change since IPO | -95.83% |
Recent News & Updates
Recent updates
Shareholder Returns
FRX | CA Biotechs | CA Market | |
---|---|---|---|
7D | 14.6% | 2.3% | 0.5% |
1Y | 34.8% | -26.3% | 8.7% |
Return vs Industry: FRX exceeded the Canadian Biotechs industry which returned -26% over the past year.
Return vs Market: FRX exceeded the Canadian Market which returned 9% over the past year.
Price Volatility
FRX volatility | |
---|---|
FRX Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 12.5% |
Market Average Movement | 8.7% |
10% most volatile stocks in CA Market | 18.3% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: FRX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FRX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 36 | Rosty Raykov | https://www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company’s product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
FRX fundamental statistics | |
---|---|
Market cap | CA$405.96m |
Earnings (TTM) | -CA$21.73m |
Revenue (TTM) | CA$28.78m |
14.1x
P/S Ratio-18.7x
P/E RatioIs FRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FRX income statement (TTM) | |
---|---|
Revenue | US$21.25m |
Cost of Revenue | US$1.26m |
Gross Profit | US$19.99m |
Other Expenses | US$36.04m |
Earnings | -US$16.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.59 |
Gross Margin | 94.08% |
Net Profit Margin | -75.50% |
Debt/Equity Ratio | -266.2% |
How did FRX perform over the long term?
See historical performance and comparison